GSK, Oxford University develop cancer vaccine targeting pre-cancerous cells

The University of Oxford and pharmaceutical giant GSK are collaborating on a pioneering cancer vaccine aimed at preventing the disease from developing by targeting pre-cancerous cells. This innovative approach is part of the GSK-Oxford Cancer Immuno-Prevention Programme, backed by a £50 million investment from GSK. Professor Sarah Blagden, co-leader of the project, highlighted that while cancers typically take years, sometimes decades, to develop, they often remain undetectable during their pre-cancer stage. The vaccine seeks to intervene at this early point to halt the progression of cancer before it manifests. This research builds on Oxford's expertise in pre-cancer biology, including the identification of specific proteins that could be targeted for vaccine development. The initiative is seen as a significant advancement in cancer research, offering hope for early intervention and prevention strategies.